Drug Candidates for Autoimmune Diseases

Abstract

Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.

Autoren

Sabrina Saurin
Myriam Meineck
Gerhard Erkel
Till Opatz
Julia Weinmann-Menke
Andrea Pautz

DOI

10.3390/ph15050503

eISSN

1424-8247

Ausgabe der Veröffentlichung

5

Zeitschrift

Pharmaceuticals

Sprache

en

Online publication date

2022

Paginierung

503 - 503

Status

Published online

Herausgeber

MDPI AG

Herausgeber URL

http://dx.doi.org/10.3390/ph15050503

Datum der Datenerfassung

2022

Titel

Drug Candidates for Autoimmune Diseases

Ausgabe der Zeitschrift

15

Datenquelle: Crossref

Abstract

Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.

Addresses

1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.

Autoren

Sabrina Saurin
Myriam Meineck
Gerhard Erkel
Till Opatz
Julia Weinmann-Menke
Andrea Pautz

DOI

10.3390/ph15050503

eISSN

1424-8247

Externe Identifier

PubMed Identifier: 35631330
PubMed Central ID: PMC9143092

Funding acknowledgements

Deutsche Forschungsgemeinschaft: Op90/13-1
Deutsche Forschungsgemeinschaft: ER 176/12-1
Deutsche Forschungsgemeinschaft: WE5779/4-1

Open access

true

ISSN

1424-8247

Ausgabe der Veröffentlichung

5

Zeitschrift

Pharmaceuticals (Basel, Switzerland)

Sprache

eng

Medium

Electronic

Online publication date

2022

Open access status

Open Access

Paginierung

503

Datum der Veröffentlichung

2022

Status

Published

Publisher licence

CC BY

Datum der Datenerfassung

2022

Titel

Drug Candidates for Autoimmune Diseases.

Sub types

review-article
Review
Journal Article

Ausgabe der Zeitschrift

15

Files

https://www.mdpi.com/1424-8247/15/5/503/pdf?version=1650507352 https://europepmc.org/articles/PMC9143092?pdf=render

Datenquelle: Europe PubMed Central

Abstract

Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.

Date of acceptance

2022

Autoren

Sabrina Saurin
Myriam Meineck
Gerhard Erkel
Till Opatz
Julia Weinmann-Menke
Andrea Pautz

Autoren-URL

https://www.ncbi.nlm.nih.gov/pubmed/35631330

DOI

10.3390/ph15050503

Externe Identifier

PubMed Central ID: PMC9143092

Funding acknowledgements

Deutsche Forschungsgemeinschaft: ER 176/12-1
Deutsche Forschungsgemeinschaft: Op90/13-1
Deutsche Forschungsgemeinschaft: WE5779/4-1

ISSN

1424-8247

Ausgabe der Veröffentlichung

5

Zeitschrift

Pharmaceuticals (Basel)

Schlüsselwörter

autoimmunity
inflammation
macrolactone
natural products

Sprache

eng

Country

Switzerland

PII

ph15050503

Datum der Veröffentlichung

2022

Status

Published online

Titel

Drug Candidates for Autoimmune Diseases.

Sub types

Journal Article
Review

Ausgabe der Zeitschrift

15

Datenquelle: PubMed

Author's licence

CC-BY

Autoren

Sabrina Saurin
Myriam Meineck
Gerhard Erkel
Till Opatz
Julia Weinmann-Menke
Andrea Pautz

Hosting institution

Universitätsbibliothek Mainz

Sammlungen

DFG-491381577-G

Resource version

Published version

DOI

10.3390/ph15050503

Funding acknowledgements

Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577

File(s) embargoed

false

Open access

true

ISSN

1424-8247

Ausgabe der Veröffentlichung

5

Zeitschrift

Pharmaceuticals

Schlüsselwörter

610 Medizin
610 Medical sciences

Sprache

eng

Open access status

Open Access

Paginierung

503

Datum der Veröffentlichung

2022

Public URL

https://openscience.ub.uni-mainz.de/handle/20.500.12030/8582

Herausgeber

MDPI

Datum der Datenerfassung

2023

Datum, an dem der Datensatz öffentlich gemacht wurde

2023

Zugang

Public

Titel

Drug candidates for autoimmune diseases

Ausgabe der Zeitschrift

15

Files

drug_candidates_for_autoimmun-20230112132020289.pdf

Datenquelle: OPENSCIENCE.UB

Files

Files

Werkzeuge